Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew M Hufford

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Nature Reviews. Immunology|April 20, 2021
Neutralizing monoclonal antibodies for treatment of COVID-19Peter C Taylor, Andrew C Adams, Matthew M Hufford, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2016
The ETS Family Transcription Factors Etv5 and PU.1 Function in Parallel To Promote Th9 Cell DevelopmentByunghee Koh, Matthew M Hufford, Duy Pham, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 13, 2015
PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell DevelopmentOlufolakemi Awe, Matthew M Hufford, Hao Wu, et al.
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Bioanalysis|July 22, 2021
Novel methodology comparing two assay formats for the assessment of immunogenicity from clinical trial samplesDaniel A Peterson, Thomas G Pottanat, Heather Denning, et al.
Rheumatology and Therapy|July 24, 2020
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population SurveyWilliam Tillett, Joseph F Merola, Diamant Thaçi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2023
ERG Functionally Overlaps with Other Ets Proteins in Promoting TH9 Cell Expression of Il9 during Allergic Lung InflammationRakshin Kharwadkar, Benjamin J Ulrich, Michelle Chu, et al.
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Nature Reviews. Immunology|April 20, 2021
Neutralizing monoclonal antibodies for treatment of COVID-19Peter C Taylor, Andrew C Adams, Matthew M Hufford, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2016
The ETS Family Transcription Factors Etv5 and PU.1 Function in Parallel To Promote Th9 Cell DevelopmentByunghee Koh, Matthew M Hufford, Duy Pham, et al.
Infectious Diseases and Therapy|September 4, 2024
Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19Dipak R Patel, Lisa Macpherson, Martin Bohm, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 13, 2015
PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell DevelopmentOlufolakemi Awe, Matthew M Hufford, Hao Wu, et al.
Annals of the Rheumatic Diseases|May 23, 2019
The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studiesArthur Kavanaugh, Alice Gottlieb, Akimichi Morita, et al.
Arthritis Research & Therapy|January 27, 2021
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studiesBernard Combe, Tsen-Fang Tsai, J Eugene Huffstutter, et al.
Bioanalysis|July 22, 2021
Novel methodology comparing two assay formats for the assessment of immunogenicity from clinical trial samplesDaniel A Peterson, Thomas G Pottanat, Heather Denning, et al.
Rheumatology and Therapy|July 24, 2020
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population SurveyWilliam Tillett, Joseph F Merola, Diamant Thaçi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 13, 2023
ERG Functionally Overlaps with Other Ets Proteins in Promoting TH9 Cell Expression of Il9 during Allergic Lung InflammationRakshin Kharwadkar, Benjamin J Ulrich, Michelle Chu, et al.
Open Forum Infectious Diseases|May 2, 2022
Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.
Pageof 3